Identification of an immunogenic subset of metastatic uveal melanoma · Identification of an immunogenic subset of metastatic uveal melanoma Luke D. Rothermel*1, Arvind C. Sabesan*1,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Identification of an immunogenic subset of metastatic uveal melanoma Luke D. Rothermel*1, Arvind C. Sabesan*1, Daniel J. Stephens*1, Smita S. Chandran1, Biman C. Paria1, Abhishek K. Srivastava1, Robert Somerville1, John R. Wunderlich1, Chyi-Chia R. Lee2, Liqiang Xi2, Trinh H. Pham2, Mark Raffeld2, Parthav Jailwala3, Manjula Kasoji3, and Udai S. Kammula*1
* Contributed equally as first author 1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 2 Laboratory of Pathology, National Cancer Institute, Bethesda, MD National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 3 Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research Inc., Frederick, MD 21702 Running title: Identification of an immunogenic subset of metastatic uveal melanoma Key Words: Uveal melanoma, cutaneous melanoma, T cells, liver metastases Disclosures: There are no commercial or financial disclosures. Number of figures/ tables: 5/2 Number of references: 50 Correspondence: Udai S. Kammula, MD Surgery Branch, Center for Cancer Research National Cancer Institute 10 Center Drive Building 10-Hatfield CRC, Rm 3-5930 Bethesda, MD, 20892-1201 Tel: 301-435-8606 Fax: 301-435-5167 Email: [email protected]
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
(1) Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999;9:575-81.
(2) Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881-5.
(3) Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 2012;18:148-52.
(4) de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997;57:3223-9.
(5) de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 1998;78:1156-61.
(6) Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, et al. Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clin Cancer Res 2014;20:2607-16.
(7) Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012;25:171-81.
(8) Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014;14:135-46.
(9) Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
(10) Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
(11) Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
(12) Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
(13) Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 2008;49:2518-25.
(14) McKenna KC, Chen PW. Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm 2010;18:80-90.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
(15) Niederkorn JY. Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? Front Immunol 2012;3:148.
(16) Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, et al. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007;85:617-25.
(17) Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
(18) Dorval T, Fridman WH, Mathiot C, Pouillart P. Interleukin-2 therapy for metastatic uveal melanoma. Eur J Cancer 1992;28A:2087.
(19) Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013;119:3687-95.
(20) Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013;24:2911-5.
(21) Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res 2015.
(22) Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-42.
(23) Bioinformatics.babraham.ac.uk. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data Internet] 2015 ;http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. cited March 20 , 2015
(24) Patel RK, Jain M. NGS QC Toolkit: a toolkit for quality control of next generation sequencing data. PLoS One 2012;7:e30619.
(25) Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014;30:2114-20.
(26) Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-95.
(27) Institute G. GATK | Best Practice Workflows [Internet]. Broadinstituteorg. 2015; https://www.broadinstitute.org/gatk/guide/best-practices. cited March 30 , 2015
(28) Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
(29) Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
(30) Gdac.broadinstitute.org. [Internet]2015 ;http://gdac.broadinstitute.org/runs/stddata__2014_07_15/data/SKCM/20140715/gdac.broadinstitute.org_SKCM.Mutation_Packager_Calls.Level_3.2014071500.0.0.tar.gz. cited March 20 , 2015
(31) Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178-92.
(32) Egberts F, Bergner I, Kruger S, Haag J, Behrens HM, Hauschild A, et al. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 2014;25:246-50.
(33) Premkumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruber D. Metastatic melanoma: correlation of MRI characteristics and histopathology. J Magn Reson Imaging 1996;6:190-4.
(34) Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
(35) Liu H, Zhang T, Ye J, Li H, Huang J, Li X, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1849-56.
(36) Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959-66.
(37) Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
(38) Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
(39) Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5.
(40) Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
(41) Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
(42) Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
(43) Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De G, V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522-9.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
(44) Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
(45) Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
(46) Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
(47) Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012;490:412-6.
(48) Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
(49) Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
(50) Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000;23:17-27.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294
Published OnlineFirst December 28, 2015.Clin Cancer Res Luke D. Rothermel, Arvind Sabesan, Daniel J. Stephens, et al. melanomaIdentification of an immunogenic subset of metastatic uveal
Updated version
10.1158/1078-0432.CCR-15-2294doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2015/12/23/1078-0432.CCR-15-2294To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2294